CytoDyn Inc (OTCMKTS:CYDY) a biotechnology firm focused on the advancement of new monoclonal antibody treatments for combating HIV infection, reported that Nader Pourhassan, Ph.D., the CEO and President, will present at the upcoming LD Micro Main Event scheduled on December 7 in Los Angeles.
Prior to this update, CytoDyn reported that an abstract showcasing results from its underway Phase 2b extension trial with PRO 140 as a monotherapy for the cure of HIV patients has been approved for a poster presentation, and a themed discussion at the CROI, which will be held in Seattle in February 2017.
The abstract was chosen for a themed discussion by the CROI Program Committee. It will comprise four or five abstracts combined into a distinct theme-oriented, hour-long talk featuring a summary of noteworthy conclusions, discussion points and results. These presentations will be trailed by an interactive conversation that synthesizes the applicable information of the abstracts, includes main points of controversy and agreement and draws comparisons to linked work in the scientific field.
CytoDyn abstract will offer an update on ten HIV patients who have recorded complete viral load suppression for over 2 years with PRO 140 given in weekly subcutaneous injections. Entire virologic suppression is stated as plasma HIV-1 RNA coming less than 40 copies/mL. It is the lower range of detection in the viable assay for HIV diagnosis and is the mark at which HIV transmission is minimized by over 96%.
Nader Pourhassan, Ph.D., the CEO and President of CytoDyn, said that the report from this underway extension trial is highly notable as PRO 140 is being replaced for the existing standard of care HAART. Only nearly 30% of patients’ witness lifetime viral load dominance on HAART, which even has notable downsides such as toxicity, partial recovery of the immune system and highly regimented daily dosing. All patients in the Phase IIb monotherapy trial were assessed for infection with HIV-1 strains that use the CCR5 co-receptor.